The American Society of Breast Surgeons
Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

https://doi.org/10.1016/j.amjsurg.2008.06.021Get rights and content

Abstract

Background

Oncotype DX is a 21-gene assay that calculates a risk of distant recurrence in women with estrogen-receptor–positive, lymph node–negative breast cancer. The purpose of this study was to determine whether the results of Oncotype DX influence the decision to administer chemotherapy.

Methods

A retrospective study was performed on 85 consecutive patients with estrogen-receptor–positive, lymph node–negative breast cancer who had an Oncotype DX recurrence score (RS) obtained. Tumor size, tumor grade, and treatment were then compared within each risk category. Statistical analysis was performed using STATA software.

Results

Tumors that were high grade and Her-2/neu positive more frequently had a high RS. Treatment was changed as a result of Oncotype DX in 44% of patients.

Conclusions

Oncotype DX RS is significantly related to tumor grade and Her2/neu status. In this study, the treatment of 44% of patients was altered as a consequence of Oncotype DX RS.

References (6)

There are more references available in the full text version of this article.

Cited by (117)

  • Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption

    2020, Clinical Breast Cancer
    Citation Excerpt :

    We did not have access to genomic recurrence risk scores. Other studies have examined this topic at length, albeit in smaller clinic-based samples rather than population-based samples, and have demonstrated an overall deescalation in chemotherapy use with receipt of the 21-gene assay, particularly in women with low-risk disease.3,4,8,21,22 A primary challenge to interpreting the impact of the 21-gene assay on chemotherapy use is the selective administration of the test, which has been reported by our group in a partly overlapping earlier cohort (2004-2009) of women with newly diagnosed, nonmetastatic, invasive breast cancer.

  • Short-chain fatty acids production by Bifidobacterium species in the presence of salep

    2020, Electronic Journal of Biotechnology
    Citation Excerpt :

    When fermentation substrates such as prebiotics are consumed by both animals and humans, the acidity in the colon decreases depending on the structure and dose of the prebiotics. Lower pH values result in a decrease in the growth of pathogenic bacteria and an increase in the growth of beneficial microbiota (e.g., Bifidobacteria and Lactobacilli) [8]. Thus, pH is a critical value to assess the effectiveness of candidate prebiotics in in vitro and in vivo models.

  • Diagnostic Pathology: Breast

    2017, Diagnostic Pathology: Breast
  • The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy

    2016, European Journal of Cancer
    Citation Excerpt :

    Although a recent systematic review found no studies to support the clinical utility of GEP (i.e. direct evidence that using GEP to direct treatment decisions improved outcomes in women with breast cancer) [14], previous qualitative research has demonstrated that patients consider GEP results a deciding factor in treatment decisions [15]. Multiple studies have examined how GEP results impact or change treatment decisions in breast cancer patients [16–22]; however, studies are lacking about the impact of GEP on decisional conflict in women from the general population, who are at risk of breast cancer and may ultimately face a decision about GEP. This is important to understand, especially in a publicly funded healthcare system where healthcare decision makers make resource allocation decisions for the population, and are increasingly incorporating public values into reimbursement decisions [23].

View all citing articles on Scopus
View full text